Although studies by Ding et al. revealed how the R167Q VHL mutation contributes to tumorigenesis and identified a potential targeted therapy for ccRCC and other VHL-related disease in patients carrying R167Q mutation or similar missense mutations [17], the specific role of the R167Q VHL mutation and selective transcriptional regulation remains largely unknown. Here, VHL is linked to nonpapillary renal cell carcinoma.